M, de Snoo F, Engelen K, Russo L, Dell'Orto P, Glas A, Cardoso F, on behalf of the TRANSBIG Consortium & the MINDACT Investigators. European Institute of Oncology, Milan, Italy; European Organisation of Research and Treatment of Cancer, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, Netherlands; Institute Jules Bordet, Brussels, Belgium; AgendiaNV, Amsterdam, Netherlands; Champalimaud Cancer Center, Lisboa, Portugal.
Date: Thursday, December 8th
Time: 5:00pm – 7:00pm
Poster presentation (OT2-03-02): Prospective Neo-Adjuvant Registry Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST)
Lead authors: Whitworth P, Beitsch P, Gittleman M, Akbari S. Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA.
Date: Thursday, December 8th
Time: 5:00pm – 7:00pm
Poster presentation (P3-04-06): Comparison of MammaPrint, BluePrint, and TargetPrint with Clinical Parameters in Patients with Breast Cancer: Findings from a Prospective United States Cohort
Lead authors: Nguyen B, Sinha R, Kerlin D, Barone J, Garcia A, Yao K, Rivera E, Stork-Sloots L, Deck K. Long Beach Memorial Health Care, Long Beach, CA; Rockwood Clinic, Spokane, WA; John Muir, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; University of Southern California, Los Angeles, CA; North Shore University Health System, Chicago, IL; The Methodist Hospital/Weill Cornell University, Houston, TX; Agendia Inc, Irvine, CA; Saddleback Memorial Medical Center, Laguna Hills, CA.
Date: Friday, December 9th
Time: 5:00pm – 7:00pm
Poster presentation (P5-11-09): High Concordance for Microarray Based Determination of ER, PR and HER2 R
'/>"/>
SOURCE Agendia Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study2.
Agendia Successfully Completes Bi-Annual FDA Inspection3.
Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting4.
Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists5.
Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)6.
Agendia Raises US $23 Million in Series E Financing7.
Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards8.
Agendia Opens CLIA-Registered U.S. Genomics Laboratory9.
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting10.
Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference11.
Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference